Tagged with Novartis,

Mexico Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing innovative treatments to what is a still-developing market.   A new set of rules is emerging in Mexican healthcare Fernando,…

UAE Georg Schroeckenfuchs, Novartis’ president for the Middle East and head of MEA cluster, is a 32-year veteran of the pharmaceutical industry and describes the company’s footprint within the MEA region, provides insights into its strategy of segmenting their markets into three categories. Furthermore, he discusses the company’s strategic priorities when…

Czech Republic Martin Puchwein, country president for Novartis Group Czech Republic, and general manager for pharma, shares his perspectives on launching innovative drugs in the country, including some new therapeutic approaches such as cell and gene therapies. Puchwein also discusses Novartis’ ambition to transform its corporate culture towards becoming an organization where…

Brazil Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases.   This agreement establishes an exchange of know-how that will provide progress in public health policies in Brazil Patrice Matchaba, global head of corporate responsibility, Novartis…

Switzerland With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard of countering a disease which the World Health Organization (WHO) predicts will reach an incidence rate of 22 million new…

Sweden Judith Love, country president Sweden and oncology general manager for the Nordics region for Novartis, underlines the need for a new reimbursement system for cell and gene therapies in the region and explains how the Nordics and Sweden can be a pioneer in this field, by initiating early dialogue between…

China Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at the top leadership level but throughout the organization. A few country managers share their talent strategies, as well as the…

Thailand Sumalee Kristarnin, country president of Novartis Thailand, shares the main initiatives of the affiliate in Thailand to take care of people, employees and patients. She highlights how the key priorities, put in place at the global level, are reflected in the local business, and how Novartis is trying to introduce…

China Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of…

Cell & Gene Therapy Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as younger people with disabilities, has recently announced it will be increasing reimbursement rates and expanding coverage for cell and gene therapy treatments, good news for cancer patients and pharma companies Gilead…

Sweden The Top 20 pharma companies in Sweden ranked by sales in 2018. Out in front is Swiss giant Novartis with approx USD 256 million in sales, followed by MSD with USD 220 million and Pfizer with USD 212 million. The companies with the highest levels of sales growth since 2017…

China Ingrid Zhang, president of Novartis Pharmaceuticals China, shares the transformation of Novartis China in the past two years in line with the global Novartis vision; their aspiration to become a powerhouse for bringing innovative products to China and to develop talents; their commitment to working with various stakeholders to promote…